GlassScriptPhysician profile
Sarah E Snyder
NPI 1689906968
$4,255.40
in general payments reported to CMS, 2019-2025
33 companies · $699 in 2025
The $699 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $992 · 2022: $801 · 2023: $944 · 2024: $820 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,462.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,256.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $389.51 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Lilly USA, LLC | $332.11 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $262.44 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.17 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $184.52 | 2021-2024 | Veozah |
| Amgen INC. | $156.85 | 2021-2024 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $140.28 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $138.29 | 2021-2025 | Airsupra, Farxiga |
| Abbvie INC. | $138.27 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $115.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $102.35 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.45 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $94.97 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Inspire Medical Systems, INC. | $94.00 | 2023-2025 | Inspire |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $65.17 | 2021-2025 | General - Erectile Dysfunction |
| Sanofi-Aventis U.S. LLC | $64.72 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.56 | 2022 | |
| Mannkind Corporation | $41.36 | 2022 | |
| Glaxosmithkline, LLC. | $39.85 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $35.68 | 2021-2022 | |
| Daiichi Sankyo INC. | $35.20 | 2023-2024 | Injectafer |
| Exact Sciences Corporation | $30.98 | 2025 | The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $26.50 | 2022-2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $23.63 | 2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $21.63 | 2025 | Gemtesa |
| Vbi Vaccine (Delaware) INC. | $20.00 | 2023 | Prehevbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.99 | 2022 | |
| Lucid Diagnostics INC. | $18.50 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2024 | Eliquis |
| Dynavax Technologies Corporation | $14.80 | 2025 | Heplisav-B |
| Arbor Pharmaceuticals, INC. | $13.36 | 2021 | |
| Almatica Pharma LLC | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.